Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

A 2-Year Observational Study in Patients Suffering from Idiopathic Pulmonary Fibrosis and Treated with Pirfenidone: A French Ancillary Study of PASSPORT.

Jouneau S, Gamez AS, Traclet J, Nunes H, Marchand-Adam S, Kessler R, Israël-Biet D, Borie R, Strombom I, Scalori A, Crestani B, Valeyre D, Cottin V.

Respiration. 2019 Apr 9:1-10. doi: 10.1159/000496735. [Epub ahead of print]

PMID:
30965332
2.

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study.

Cottin V, Koschel D, Günther A, Albera C, Azuma A, Sköld CM, Tomassetti S, Hormel P, Stauffer JL, Strombom I, Kirchgaessler KU, Maher TM.

ERJ Open Res. 2018 Oct 19;4(4). pii: 00084-2018. doi: 10.1183/23120541.00084-2018. eCollection 2018 Oct.

3.

Comparison of antidepressant classes and the risk and time course of suicide attempts in adults: propensity matched, retrospective cohort study.

Valuck RJ, Libby AM, Anderson HD, Allen RR, Strombom I, Marangell LB, Perahia D.

Br J Psychiatry. 2016 Mar;208(3):271-9. doi: 10.1192/bjp.bp.114.150839. Epub 2015 Dec 3.

PMID:
26635328
4.

Treatment with duloxetine in adults and the incidence of cardiovascular events.

Xue F, Strombom I, Turnbull B, Zhu S, Seeger J.

J Clin Psychopharmacol. 2012 Feb;32(1):23-30. doi: 10.1097/JCP.0b013e31823fb238.

PMID:
22198454
5.

Duloxetine for depression and the incidence of hepatic events in adults.

Xue F, Strombom I, Turnbull B, Zhu S, Seeger JD.

J Clin Psychopharmacol. 2011 Aug;31(4):517-22. doi: 10.1097/JCP.0b013e31822347d9.

PMID:
21694615
6.

Hepatic effects of duloxetine-III: analysis of hepatic events using external data sources.

Strombom I, Wernicke JF, Seeger J, D'Souza DN, Acharya N.

Curr Drug Saf. 2008 May;3(2):154-62.

PMID:
18690993
7.

Hepatic effects of duloxetine-II: spontaneous reports and epidemiology of hepatic events.

Wernicke J, Acharya N, Strombom I, Gahimer JL, D'Souza DN, DiPietro N, Uetrecht JP.

Curr Drug Saf. 2008 May;3(2):143-53. Review.

PMID:
18690992
8.

Answers to the most common questions about the hepatic safety profile of duloxetine.

Wohlreich MM, Acharya N, Strombom I, Kuritzky L, Robinson M, Heinloth AN, Regev A, Wernicke JF.

Postgrad Med. 2008 Jul;120(2):111-8. doi: 10.3810/pgm.2008.07.1803. Review.

PMID:
18654076
9.

Ecological studies of antidepressant treatment and suicidal risks.

Baldessarini RJ, Tondo L, Strombom IM, Dominguez S, Fawcett J, Licinio J, Oquendo MA, Tollefson GD, Valuck RJ, Tohen M.

Harv Rev Psychiatry. 2007 Jul-Aug;15(4):133-45. Review.

PMID:
17687708
10.

Awareness of potential valvulopathy risk with pergolide and changes in clinical practice after label change: a survey among European neurologists.

Lledó A, Dellva MA, Strombom IM, Wilkie JL, Jungemann ME, Royer MG, Simmons VE, Cavazzoni PA.

Eur J Neurol. 2007 Jun;14(6):644-9.

PMID:
17539942
11.

Socioeconomic risk factors for breast cancer: distinguishing individual- and community-level effects.

Robert SA, Strombom I, Trentham-Dietz A, Hampton JM, McElroy JA, Newcomb PA, Remington PL.

Epidemiology. 2004 Jul;15(4):442-50.

PMID:
15232405
12.

Setting a national research agenda in nursing informatics.

Brennan PF, Zielstorff RD, Ozbolt JG, Strombom I.

Stud Health Technol Inform. 1998;52 Pt 2:1188-91.

PMID:
10384647
13.

Improving health care by understanding patient preferences: the role of computer technology.

Brennan PF, Strombom I.

J Am Med Inform Assoc. 1998 May-Jun;5(3):257-62.

Supplemental Content

Loading ...
Support Center